Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleogel S10

Drug Profile

Oleogel S10

Alternative Names: AP 101; Betulin-based oleogel; Birch-triterpene; Episalvan; Oleogel-S10; Sericare

Latest Information Update: 12 Sep 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Birken GmbH
  • Developer Amryt Pharma
  • Class Herbal medicines; Skin disorder therapies; Triterpenes
  • Mechanism of Action Keratinocyte modulators; Transient receptor potential channel stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Registered Wounds
  • Phase III Burns; Epidermolysis bullosa
  • Phase II Actinic keratosis

Most Recent Events

  • 10 Sep 2018 US FDA approves IND application for oleogel S10 in Epidermolysis Bullosa
  • 02 Aug 2018 Oleogel S10 receives Rare Pediatric Disease Designation for Epidermolysis bullosa in USA
  • 29 Mar 2017 Phase-III clinical trials in Epidermolysis bullosa (In adolescents, In children, In the elderly, In adults) in Spain (Topical) (EudraCT2016-002066-32)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top